The pamoras, their utilitites and advances in the treatment of side effects opiod on mu receptors
Keywords:
Analgesics, Opioid-related disorders, MuAbstract
The aim of this paper is to review the state of knowledge of the utilities of the Pamoras in treating the collateral ef- fects of opioids with mu receptors. We searched the scientific literature between the years 2001-2010 from which we conclude that Pamoras, particularly methylnaltrexone and alvimopan have proved useful in the treatment of gastrointestinal effects, to the extent that its use has been approved by the Food and Drug Administration. Prob- ably other undesirable effects of opioids such as urinary retention, nausea and itching may also be treated with these substances, but additional research is needed. In addition, intensively studied the effects of actions on other cellular pamoras undesirable opiates, such as tumor growth and increased vascular permeability. The actions are mediated primarily by peripheral mu receptor antagonism.
Downloads
Download data is not yet available.
References
1.Schwartz AJ, Moss J, Foss J. Pain relief without side effects: peripheral opiate antagonists. In: Schwartz AJ, ed. ASA Refresher Courses in Anesthesiology. Vol Philadelphia, PA: Lippin- cott Williams and Wilkins. 2005:175-86.
2.Moss J. Rosow CE. Development of peri- pheral opioid antagonists: New Insights Into Opioid Effects. Mayo Clin Proc. 2008; 83(10):1116-30.
3.US Food and Drug Administration. FDA ap- proves Relistor for opioid-induced constipa- tion. [homepage on the Internet]. Maryland; [updated 2008 April 24; cited 2008 Aug 29]. Available from: http://www.fda.gov/bbs/to- pics/NEWS/2008/NEW01826.html
4.US Food and Drug Administration. FDA appro- ves Entereg to help restore bowel function following surgery. [homepage on the In- ternet]. Maryland; [updated 2008 May 20; cited 2008 Aug 27]. Available from: http:// www.fda.gov/bbs/topics/NEWS/2008/ NEW01838.html
5.Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid boweldys function and other opioid adverse effects. Ann Pharmacother. 2007; 41(6):984-93.
6.Büchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal sur- gery: results of an international randomized, double-blind, multicentre, placebo-contro- lled clinical study. Aliment Pharmacol Ther. 2008;28: 312-25.
7.Cassel JA, Daubert JD, DeHaven RN. [(3) H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005; 520(1-3):29-36.
8.Doyle D, Hanks G, Cherry N, Calman K, Sykes N. Constipation and diarrhoea. In: Doyle D, Hanks G, Cherry N, Calman K, eds. Oxford Textbook of Palliative Medicine. 3rd ed. New York, NY: Oxford University Press; 2004:483-96.
9.Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, et al. Alvimopan Posto- perative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioide antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005; 48(6):1114-25.
10.Leslie J, Bell T, Annunziata K, Freedman D. Opioid-induced constipation compromises pain management and impacts patient quali- ty of life. Anesthesiology. 2006; 105: A1490. 11.Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic techni- que for radical prostatectomy surgery affects cancer recurrence: a retrospectivwe analy- sis. Anesthesiology. 2008; 109(2):180-87.
12.Exadaktylos AK, Buggy DJ, Moriarty DC, Mas- cha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect re- currence or metastasis?. Anesthesiology. 2006;105 (4):660-64.
13.Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl):11S-18S.
14.Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001; 182(5A)(suppl):3S- 10S.
15.Kurz A, Sessler DI. Opioid-induced bowel dys- function: pathophysiology and potential new therapies. Drugs. 2003; 63(7):649-71.
16.Maron DJ, Fry RD. New therapies in the treatment of postoperative ileus after gas- trointestinal surgery. Am J Ther. 2008; 15(1):59-65.
17.Shook JE, Pelton JT, Hruby FJ, Burks TF. Pep- tide opioid antagonist separates peripheral and central opioid antitransit effects. J Phar- macol Exp Ther. 1987; 243(2):492-500.
18.Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Dis- covery of a potent, peripherally selective trans-3,4-dimethyl-4-(3- hydroxyphenyl) pi- peridine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994; 37(15):2262-65.
19.Yuan CS, Doshan H, Charney MR, O’connor M, Karrison T, Maleckar SA, et al. Tolerability, gut effects, and pharmacokinetics of methyl- naltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005; 45(5):538-46.
20.Sessler DI, Ben-Eliyahu S, Mascha EJ, Parat MO, Buggy DJ. Can regional analgesia redu- ce the risk of recurrence after breast cancer? methodology of a multicenter randomized trial. Contemp Clin Trials. 2008; 29(4):517-26.
21.Ho WZ, Guo CJ, Yuan CS, Douglas SD, Moss J. Methylnaltrexone antagonizes opioid-me- diated enhancement of HIV infection of hu- man blood mononuclear phagocytes. J Phar- macol Exp Ther. 2003; 307(3):1158-62.
22.Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, et al. HIV-1 variation be- fore seroconversion in men who have sex with men: analysis of acute/early HIV infec- tion in the multicenter AIDS cohort study. J Infect Dis. 2008; 197(7):1011-15.
23.Keele BF, Giorgi EE, Salazar-Gonzalez JF, Dec- ker J, Pham K, Salazar M, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 in- fection. Proc Natl Acad Sci U S A. 2008; 105 (21):7552-57.
2.Moss J. Rosow CE. Development of peri- pheral opioid antagonists: New Insights Into Opioid Effects. Mayo Clin Proc. 2008; 83(10):1116-30.
3.US Food and Drug Administration. FDA ap- proves Relistor for opioid-induced constipa- tion. [homepage on the Internet]. Maryland; [updated 2008 April 24; cited 2008 Aug 29]. Available from: http://www.fda.gov/bbs/to- pics/NEWS/2008/NEW01826.html
4.US Food and Drug Administration. FDA appro- ves Entereg to help restore bowel function following surgery. [homepage on the In- ternet]. Maryland; [updated 2008 May 20; cited 2008 Aug 27]. Available from: http:// www.fda.gov/bbs/topics/NEWS/2008/ NEW01838.html
5.Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid boweldys function and other opioid adverse effects. Ann Pharmacother. 2007; 41(6):984-93.
6.Büchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal sur- gery: results of an international randomized, double-blind, multicentre, placebo-contro- lled clinical study. Aliment Pharmacol Ther. 2008;28: 312-25.
7.Cassel JA, Daubert JD, DeHaven RN. [(3) H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005; 520(1-3):29-36.
8.Doyle D, Hanks G, Cherry N, Calman K, Sykes N. Constipation and diarrhoea. In: Doyle D, Hanks G, Cherry N, Calman K, eds. Oxford Textbook of Palliative Medicine. 3rd ed. New York, NY: Oxford University Press; 2004:483-96.
9.Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, et al. Alvimopan Posto- perative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioide antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005; 48(6):1114-25.
10.Leslie J, Bell T, Annunziata K, Freedman D. Opioid-induced constipation compromises pain management and impacts patient quali- ty of life. Anesthesiology. 2006; 105: A1490. 11.Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic techni- que for radical prostatectomy surgery affects cancer recurrence: a retrospectivwe analy- sis. Anesthesiology. 2008; 109(2):180-87.
12.Exadaktylos AK, Buggy DJ, Moriarty DC, Mas- cha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect re- currence or metastasis?. Anesthesiology. 2006;105 (4):660-64.
13.Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A suppl):11S-18S.
14.Kehlet H, Holte K. Review of postoperative ileus. Am J Surg. 2001; 182(5A)(suppl):3S- 10S.
15.Kurz A, Sessler DI. Opioid-induced bowel dys- function: pathophysiology and potential new therapies. Drugs. 2003; 63(7):649-71.
16.Maron DJ, Fry RD. New therapies in the treatment of postoperative ileus after gas- trointestinal surgery. Am J Ther. 2008; 15(1):59-65.
17.Shook JE, Pelton JT, Hruby FJ, Burks TF. Pep- tide opioid antagonist separates peripheral and central opioid antitransit effects. J Phar- macol Exp Ther. 1987; 243(2):492-500.
18.Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Dis- covery of a potent, peripherally selective trans-3,4-dimethyl-4-(3- hydroxyphenyl) pi- peridine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994; 37(15):2262-65.
19.Yuan CS, Doshan H, Charney MR, O’connor M, Karrison T, Maleckar SA, et al. Tolerability, gut effects, and pharmacokinetics of methyl- naltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005; 45(5):538-46.
20.Sessler DI, Ben-Eliyahu S, Mascha EJ, Parat MO, Buggy DJ. Can regional analgesia redu- ce the risk of recurrence after breast cancer? methodology of a multicenter randomized trial. Contemp Clin Trials. 2008; 29(4):517-26.
21.Ho WZ, Guo CJ, Yuan CS, Douglas SD, Moss J. Methylnaltrexone antagonizes opioid-me- diated enhancement of HIV infection of hu- man blood mononuclear phagocytes. J Phar- macol Exp Ther. 2003; 307(3):1158-62.
22.Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, et al. HIV-1 variation be- fore seroconversion in men who have sex with men: analysis of acute/early HIV infec- tion in the multicenter AIDS cohort study. J Infect Dis. 2008; 197(7):1011-15.
23.Keele BF, Giorgi EE, Salazar-Gonzalez JF, Dec- ker J, Pham K, Salazar M, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 in- fection. Proc Natl Acad Sci U S A. 2008; 105 (21):7552-57.
Downloads
Published
2011-12-01
Issue
Section
Articles
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
How to Cite
The pamoras, their utilitites and advances in the treatment of side effects opiod on mu receptors. (2011). Biociencias, 6(2), 73-82. https://revistas.unilibre.edu.co/index.php/biociencias/article/view/2782
